Cat. No.
MABL-1929
Application
WB, ELISA, IHC
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
MsMab-1
From
Recombinant Antibody
Specificity
This antibody binds human isocitrate dehydrogenase 1 (IDH1) having R132H, R132C, R132S, R132G and R132L mutations and does not cross react with wild-type IDH1 protein. It also recognizes IDH2- R172M (GGTKPITIGMHAHGDQYKA) and IDH2-R172S (GGTKPITIGSHAHGDQYKA). IDH1 is an enzyme that catalyzes the NADP+-dependent oxidative decarboxylation of isocitrate (D-threo-isocitrate) to 2- ketoglutarate (2-oxoglutarate), which is required by other enzymes such as the phytanoyl-CoA dioxygenase. It plays a critical role in the generation of NADPH, an important cofactor in many biosynthesis pathways. The NADPH produced from isocitrate dehydrogenase 1 is involved in the breakdown of fats for energy, and it also protects cells from potentially harmful molecules called reactive oxygen species. Mutation in IDH1 are found in several genetic conditions and in some types of cancer, including gliomas, cartilaginous tumors, acute myelogenous leukemia, myelodysplastic syndromes, and brain cancer.
Alternative Names
IDH; IDH1; IDPc; Isocitrate dehydrogenase [NADP] cytoplasmic; Isocitrate dehydrogenase 1; Cytosolic NADP-isocitrate dehydrogenase; NADP(+)-specific ICDH; Oxalosuccinate decarboxylase; IDH2; Isocitrate dehydrogenase [NADP]; mitochondrial; ICD-M; IDP; NADP(+)-specific ICDH; Oxalosuccinate decarboxylase
UniProt
O75874; P48735
Immunogen
The original antibody was generated by immunizing BDF1 mice with synthetic IDH1-R132G peptide of 19 amino acids (GGVKPIIIGGHAYGDQYRA) conjugated with KLH.
Application Notes
The binding reactivity of this antibody to wild-type IDH1 and its mutants (R132H, R132C, R132S, R132G and R132L) peptides was determined using ELISA. Western blot analysis also revealed that MsMab-1 reacted with recombinant proteins of IDH1-R132H, IDH1-R132S, and IDH1-R132G, but not with wild type IDH1 and other IDH1 mutations. This antibody also recognizes IDH2-R172M protein, despite that the IDH1-R132G peptide shows only 73.7% identity with the equivalent portion of IDH2-R172M (GGTKPITIGMHAHGDQYKA). This antibody successfully stained the IDH1-R132S or IDH1-R132G-expressing glioma cells in immunohistochemistry (PMID: 23782684). This antibody can bind IDH2-R172S mutant of IDH2 in an ELISA and can recognize PA-tagged IDH2-R172S recombinant protein in a western blot. This antibody was also used to stain IDH2-R172S-expressing osteosarcoma tissues in immunohistochemistry (PMID: 24403254). A complete summary of the reactivity of this antibody towards various IDH1 and IDH2 mutants can be found in Liu et. al, 2013 (PMID: 24403254).
Antibody First Published
Kaneko et al. Establishment of a multi-specific monoclonal antibody MsMab- 1 recognizing both IDH1 and IDH2 mutations. Tohoku J Exp Med. 2013 Jun;230(2):103-9. PMID:23782684
Note on publication
Describes the generation of a multi-specific antibody that is capable of identifying both IDH1 and IDH2 mutations and can be used in the immunohistochemical determination of glioma cells.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
